Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Gabay, Cem; Fautrel, Bruno; Rech, Jürgen; Spertini, François; Feist, Eugen; Kötter, Ina; Hachulla, Eric; Morel, Jacques; Schaeverbeke, Thierry; Hamidou, Mohamed A; Martin, Thierry; Hellmich, Bernhard; Lamprecht, Peter; Schulze-Koops, Hendrik; Courvoisier, Delphine Sophie; Sleight, Andrew; Schiffrin, Eduardo Jorge

doi:10.1136/annrheumdis-2017-212608

Scientific article

Open access

English

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

ContributorsGabay, Cem; Fautrel, Bruno; Rech, Jürgen; Spertini, François; Feist, Eugen; Kötter, Ina; Hachulla, Eric; Morel, Jacques; Schaeverbeke, Thierry; Hamidou, Mohamed A; Martin, Thierry; Hellmich, Bernhard; Lamprecht, Peter; Schulze-Koops, Hendrik; Courvoisier, Delphine Sophie; Sleight, Andrew; Schiffrin, Eduardo Jorge

Published inAnnals of the Rheumatic Diseases, vol. 77, no. 6, p. 840-847

Publication date2018

Abstract

Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD.

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Mécanisme de l'inflammation articulaire (44)

Citation (ISO format)

GABAY, Cem et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. In: Annals of the Rheumatic Diseases, 2018, vol. 77, n° 6, p. 840–847. doi: 10.1136/annrheumdis-2017-212608